NASDAQ:APOP Cellect Biotechnology (APOP) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$13.10▼$13.3750-Day Range$7.54▼$13.4052-Week Range$6.64▼$35.52Volume17,400 shsAverage Volume479,845 shsMarket Capitalization$12.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cellect Biotechnology alerts: Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Cellect Biotechnology Stock (NASDAQ:APOP)Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.Read More Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE APOP Stock News HeadlinesMarch 1, 2024 | wsj.comKrystal Biotech Inc.June 23, 2023 | bizjournals.comRaleigh/Durham Biotech NewsJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 19, 2023 | seekingalpha.comSana Biotechnology Is Technically Overbought So Buy It LaterApril 19, 2023 | cnbc.comPiper Sandler says this biotech stock can outperform thanks to Alzheimer's treatmentFebruary 23, 2023 | benzinga.com$3M Bet On This Biotechnology Stock? Check Out These 3 Penny Stocks Insiders Are BuyingJanuary 30, 2023 | finance.yahoo.comGlobal Agricultural Biotechnology Market to Reach $88.9 Billion by 2030November 24, 2022 | morningstar.comWhy These Biotech Stocks Are Outperforming the MarketJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.November 16, 2022 | realmoney.thestreet.comSeeing Good Action in Biotechnology StocksSeptember 18, 2022 | fool.co.ukInvesting in Biotech: Top UK Biotech Stocks in 2022November 4, 2021 | finance.yahoo.comQuoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial OfficerNovember 2, 2021 | finance.yahoo.comQuoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, AustraliaOctober 16, 2021 | apnews.comCellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with ...October 15, 2021 | finance.yahoo.comCellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin PharmaceuticalsOctober 14, 2021 | finanznachrichten.deCellect Biotechnology Ltd.: Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin PharmaceuticalsSeptember 27, 2021 | benzinga.comWhy Cellect Biotechnology Shares Are Rising TodaySeptember 27, 2021 | finance.yahoo.comCellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin PharmaceuticalsSee More Headlines Receive APOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2018Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:APOP CUSIPN/A CIK1671502 Webwww.cellect.co Phone(729) 974-1444Fax972-9767-8750Employees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / Book2.76Miscellaneous Outstanding Shares977,000Free FloatN/AMarket Cap$12.87 million OptionableNot Optionable Beta1.87 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesShai YarkoniChief Executive Officer & DirectorAmos OferChief Operating OfficerYaron Ben-OzChief Financial OfficerKey CompetitorsApyx MedicalNASDAQ:APYXLucid DiagnosticsNASDAQ:LUCDDaxorNASDAQ:DXRT2 BiosystemsNASDAQ:TTOOAllurion TechnologiesNYSE:ALURView All Competitors APOP Stock Analysis - Frequently Asked Questions How were Cellect Biotechnology's earnings last quarter? Cellect Biotechnology Ltd. (NASDAQ:APOP) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.02. When did Cellect Biotechnology's stock split? Cellect Biotechnology shares split on Tuesday, October 26th 2021. The 2-1 split was announced on Tuesday, October 26th 2021. The newly issued shares were payable to shareholders after the closing bell on Tuesday, October 26th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Cellect Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA) and Acasti Pharma (ACST). This page (NASDAQ:APOP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellect Biotechnology Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellect Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
